Atom’s lead product, ABP-671, is in multicenter Phase 2b/3 clinical trials worldwide, including the US, for treatment of chronic gout. ABP-671 has shown good efficacy, safety and tolerability in completed clinical trials. It is more potent and significantly less toxic than existing drugs.
Another small molecule, ABP-745, has shown significant efficacy and good safety in animal models of anti-inflammation. ABP-745 has also demonstrated safety and efficacy in pre-clinical trials for acute gout and other anti-inflammation diseases and is in Phase 1 clinical trials.